Other dosage forms:
The most common side effects were nausea, diarrhea, headache, and dizziness.
This drug was discontinued due to side effects in  of patients overall,  of patients using  mg orally,  using  mg IV, and  using  mg IV/oral sequential therapy.
The most common side effects leading to discontinuation with the oral dose were nausea, diarrhea, dizziness, and vomiting.
The most common side effect leading to discontinuation with the IV dose was rash.
The most common side effects leading to discontinuation with the IV/oral sequential dose were diarrhea and pyrexia.
Common ( to ): Nausea, diarrhea, vomiting, constipation, gastrointestinal pain, abdominal pain, dyspepsia, decreased amylaseUncommon ( to ): Dry mouth, abdominal discomfort, abdominal distention, gastritis, gastroesophageal reflux disease, gastroenteritis, flatulence, increased blood amylase, increased lipase, antibiotic-associated colitis (including pseudomembranous colitis, life-threatening complications)Rare ( to ): Dysphagia, stomatitisFrequency not reported: Clostridium difficile-associated diarrhea, gastrointestinal disorder, pseudomembranous colitis, glossitis, tongue discoloration, upper abdominal pain, oral candidiasis, oral fungal infection
Decreased amylase has been reported in at least  of patients; however, it has not been determined if this laboratory abnormality was due to the drug or the underlying condition being treated.
Antibiotic-associated colitis (including pseudomembranous colitis; associated with life-threatening complications in very rare cases) was reported more often with IV therapy (with or without subsequent oral therapy).
The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial treatment.
Seizures (including grand mal convulsions) were reported more often with IV therapy (with or without subsequent oral therapy).
Cases of sensory or sensorimotor axonal polyneuropathy (affecting small and/or large axons) resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported.
Disturbed coordination leading to fall with injuries was reported, particularly in elderly patients.
Peripheral neuropathy (may be irreversible), polyneuropathy, hearing impairment (including deafness; reversible in most cases), and exacerbation of myasthenia gravis have also been reported during postmarketing experience.
Common ( to ): Headache, dizzinessUncommon ( to ): Somnolence, tremor, dysgeusia, lethargy, paresthesia, dysesthesia, hypoesthesia, syncope (i.
e.
, acute and short-lasting loss of consciousness), tinnitus, vertigo, convulsions/seizures of various clinical manifestations (including grand mal convulsions), taste disorder, sleep disordersRare ( to ): Smell disorders (including anosmia), disturbed coordination (including gait disturbances, especially due to dizziness or vertigo), disturbed attention, speech disorders, amnesia, peripheral neuropathy, polyneuropathy, hearing impairment (including deafness; usually reversible)Very rare (less than ): Ageusia, hyperesthesia, exacerbation of myasthenia gravisFrequency not reported: Aphasia, incoordination, parosmia, abnormal thinking, sensory axonal polyneuropathy, sensorimotor axonal polyneuropathy, orofacial dyskinesia, taste loss, taste perversion, tension headachePostmarketing reports: Altered coordination, disturbed coordination (leading to fall with injuries), abnormal gait
Common ( to ): QT prolongationUncommon ( to ): Atrial fibrillation, palpitations, tachycardia, angina pectoris, cardiac failure, cardiac arrest, bradycardia, hypertension, hypotension, phlebitis, increased blood pressure, prolonged ECG QT interval, ventricular tachyarrhythmias, vasodilationVery rare (less than ): Unspecified arrhythmias, torsade de pointes, cardiac arrestFrequency not reported: Abnormal ECG, arrhythmias, atrial flutter, ST-T wave changes, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia, congestive cardiac failure
QT prolongation was commonly reported in patients with hypokalemia, otherwise, it was uncommon.
Ventricular tachyarrhythmias and hypotension were reported more often with IV therapy (with or without subsequent oral therapy).
The mean QTc interval prolongation in a study of  patients using oral moxifloxacin was  msec versus  msec for a comparator group of patients using another antibiotic.
There were  outliers in the moxifloxacin group (QTc interval greater than  msec for men or  msec for women) versus  outliers in the comparator group.
In another study (n=), there were greater increases in the QT and QTc interval with  mg moxifloxacin than with  mg levofloxacin or  mg ciprofloxacin.
Elderly patients experienced more ECG abnormalities than younger patients.
Ventricular tachyarrhythmias (including very rare cases of cardiac arrest and torsade de pointes) have also been reported during postmarketing experience, usually in patients with concurrent severe underlying proarrhythmic conditions (, clinically significant bradycardia, acute myocardial ischemia).
Increased MCH, neutrophils, WBCs, albumin, and PT ratio, and decreased hemoglobin, RBCs, neutrophils, eosinophils, basophils, and PT ratio have been reported in at least  of patients; however, it has not been determined if these laboratory abnormalities were due to the drug or the underlying condition being treated.
Agranulocytosis has also been reported during postmarketing experience.
Common ( to ): Anemia, increased mean corpuscular hemoglobin (MCH), increased neutrophils, increased WBCs, increased albumin, increased prothrombin time (PT) ratio, decreased hemoglobin, decreased RBCs, decreased neutrophils, decreased eosinophils, decreased basophilsUncommon ( to ): Prolonged PT/INR increased, thrombocythemia, eosinophilia, neutropenia, thrombocytopenia, leukocytosis, leukopenia, decreased hematocrit, increased eosinophil count, prolonged activated partial thromboplastin timeRare ( to ): Abnormal thromboplastin levelVery rare (less than ): Increased prothrombin level/decreased INR, abnormal prothrombin level/INR, agranulocytosisFrequency not reported: Decreased thromboplastin, decreased prothrombin/increased INR, increased platelet count, decreased hemoglobin, increased white blood cell count, decreased PT ratioPostmarketing reports: PancytopeniaOther fluoroquinolones:-Very rare (less than ): Hemolytic anemia
Common ( to ): Increased ALT, increased bilirubin, decreased bilirubin, increased GGT, increased transaminasesUncommon ( to ): Abnormal hepatic function, increased aspartate aminotransferase, hepatic impairment (including increased lactate dehydrogenase)Rare ( to ): Jaundice, hepatitis (primarily cholestatic)Very rare (less than ): Fulminant hepatitis (potentially leading to life-threatening liver failure [including fatal cases])Frequency not reported: Acute fulminant hepatic failure, acute liver injury, abnormal liver function test, increased hepatic enzymePostmarketing reports: Hepatic failure (including fatal cases), acute hepatic necrosis
Increased and decreased bilirubin levels have been reported in at least  of patients; however, it has not been determined if these laboratory abnormalities were due to the drug or the underlying condition being treated.
Increased GGT was reported more often with IV therapy (with or without subsequent oral therapy).
A -year-old male developed jaundice, pruritus, weight loss, dark urine, elevated lever function tests (total bilirubin:  mg/dL; conjugated bilirubin:  mg/dL; alkaline phosphatase:  units/L; ALT:  units/L)  weeks after a -day course of oral moxifloxacin.
A liver biopsy showed portal inflammatory infiltrates with lymphocytes and eosinophils and predominantly casts in canaliculi.
Liver function tests normalized over  months.
A -year-old female developed acute fulminant hepatitis (transaminases up to  units/L) with hepatocellular necrosis, toxic epidermal necrolysis, and encephalopathy after  days of therapy.
The condition culminated in multiple organ failure, acute respiratory distress syndrome, and death, despite a liver transplant.
Hepatitis (primarily cholestatic) and jaundice have also been reported during postmarketing experience.
Common ( to ): Hypokalemia, decreased glucose, decreased oxygen partial pressure (pO)Uncommon ( to ): Hyperglycemia, anorexia, hyperlipidemia, decreased appetite, dehydration, increased blood uric acid, decreased food intakeRare ( to ): HyperuricemiaVery rare (less than ): HypoglycemiaFrequency not reported: Increased blood glucosePostmarketing reports: Dehydration (secondary to diarrhea or reduced fluid intake)Other fluoroquinolones:-Very rare (less than ): Hypernatremia, hypercalcemia
Increased ionized calcium, chloride, and globulin, and decreased glucose, and pO have been reported in at least  of patients; however, it has not been determined if these laboratory abnormalities were due to the drug or the underlying condition being treated.
Hypoglycemia has also been reported during postmarketing experience.
Common ( to ): Pyrexia, increased ionized calcium, increased chloride, increased globulin, superinfections (due to resistant bacteria or fungi [, oral and vaginal candidiasis])Uncommon ( to ): Fatigue, chest pain, asthenia, unspecific pain, malaise, edema, chills, chest discomfort, increased blood alkaline phosphatase, increased blood LDH, increased blood triglycerides, candidiasis, fungal infection, facial pain, feeling unwell (primarily asthenia or fatigue), painful conditions (including pain in back, chest, pelvic, extremities)Frequency not reported: Abnormal laboratory test (not specified), face edema, peripheral edema, weakness
Edema was reported more often with IV therapy (with or without subsequent oral therapy).
Common ( to ): InsomniaUncommon ( to ): Nervousness, confusional state, psychomotor hyperactivity/agitation, depression, restlessness, disorientation, anxiety, hallucinationsRare ( to ): Abnormal dreams, emotional labilityVery rare (less than ): Depersonalization, psychotic reactionsFrequency not reported: Self-endangering behaviorPostmarketing reports: Self-injurious behavior (, suicidal ideation/thoughts, suicide attempts)
Hallucination was reported more often with IV therapy (with or without subsequent oral therapy).
Psychotic reactions and/or depression, very rarely culminating in self-injurious behavior (such as suicidal ideation/thoughts or suicide attempts), have been reported during postmarketing experience.
Common ( to ): Injection site reactions, infusion site reactionsUncommon ( to ): Infusion site extravasation, infusion site thrombophlebitis/phlebitis
Uncommon ( to ): Arthralgia, myalgia, muscle spasms, musculoskeletal painRare ( to ): Tendinitis, increased muscle tone and cramping, muscle weakness, muscle cramp, muscle twitchingVery rare (less than ): Arthritis, tendon rupture, muscle rigidityFrequency not reported: Hypertonia, tendon disorder, musculoskeletal chest painPostmarketing reports: Gait disturbance (due to muscular, tendon, or joint symptoms)Other fluoroquinolones:-Very rare (less than ): Rhabdomyolysis
Tendon rupture has also been reported during postmarketing experience.
Uncommon ( to ): Allergic reactionRare ( to ): Anaphylactic/anaphylactoid reaction, allergic edema/angioedema (including laryngeal edema; potentially life-threatening)Very rare (less than ): Anaphylactic/anaphylactoid shock (potentially life-threatening)
Anaphylactic reaction, anaphylactic shock, and angioedema (including laryngeal edema) have also been reported during postmarketing experience.
Uncommon ( to ): Rash, pruritus, hyperhidrosis, erythema, allergic dermatitis, night sweats, urticaria, dry skinVery rare (less than ): Bullous skin reactions (like Stevens-Johnson syndrome or toxic epidermal necrolysis; potentially life-threatening)Frequency not reported: Maculopapular rash, purpuric rash, pustular rashPostmarketing reports: Toxic epidermal necrolysis, photosensitivity/phototoxicity reactions, Stevens-Johnson syndrome
Uncommon ( to ): Dysuria, vaginal infection, vulvovaginal pruritusFrequency not reported: Vaginitis, vulvovaginal candidiasis, vulvovaginal mycotic infection
Uncommon ( to ): Visual disturbances (including blurred vision, diplopia; especially during central nervous system [CNS] reactions)Very rare (less than ): Transient vision loss (especially during CNS reactions)Frequency not reported: Amblyopia, abnormal vision (visual disturbances temporally associated with CNS symptoms)
Vision loss (especially during CNS reactions) has also been reported during postmarketing experience; most cases were transient.
Uncommon ( to ): Increased blood creatinine, increased blood urea, renal failure, renal impairment (including increased BUN, increased creatinine)Frequency not reported: Abnormal kidney function, acute renal failurePostmarketing reports: Interstitial nephritis
Renal impairment (including increased BUN and creatinine) and renal failure (due to dehydration, particularly in elderly patients with preexisting renal disorders) were reported more often with IV therapy (with or without subsequent oral therapy).
Uncommon ( to ): Dyspnea (including asthmatic conditions), wheezing, bronchospasm, asthmaPostmarketing reports: Allergic pneumonitis, laryngeal edema
intravenous solution
Abdominal or stomach cramps
abdominal or stomach tenderness
black, tarry stools
bleeding gums
blisters
bloating or swelling of the face, arms, hands, lower legs, or feet
blood in the urine or stools
blurred vision
bone pain
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
chest pain
chills
clay-colored stools
cough
crying
dark urine
diarrhea, watery and severe, which may also be bloody
difficult or labored breathing
difficulty with moving
difficulty with swallowing
discouragement
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
dry mouth
excessive muscle tone
fainting
fast, irregular, pounding, or racing heartbeat or pulse
feeling of unreality
feeling of warmth or heat
feeling sad or empty
fever
flushed, dry skin
flushing or redness of the skin, especially on the face and neck
fruit-like breath odor
headache
hyperventilation
increased hunger
increased sensitivity of the skin to sunlight
increased thirst
increased urination
irregular heartbeat recurrent
irritability
joint pain, stiffness, or swelling
lack of coordination
loss of appetite
loss of interest or pleasure
lower back, side, or stomach pain
mood or mental changes
muscle aching or cramping
muscle pains or stiffness
muscle tension or tightness
nausea or vomiting
nervousness
noisy breathing
pain
pain in the pelvis
pain, warmth, or burning in the fingers, toes, and legs
painful or difficult urination
painful, swollen joints
pale skin
pinpoint red spots on the skin
pounding in the ears
problems with speech or speaking
problems with vision or hearing
quick to react or overreact emotionally
rapid weight gain
rapidly changing moods
redness or other discoloration of the skin
restlessness
seeing, hearing, or feeling things that are not there
seizures
sensation of the skin burning
sense of detachment from self or body
severe sunburn
shakiness in the legs, arms, hands, or feet
skin rash or itching
sore throat
sores, ulcers, or white spots on the lips or in the mouth
sweating
swelling of the feet or lower legs
swelling or puffiness of the face
swollen glands
tightness in the chest
tingling of the hands or feet
tiredness
trouble concentrating
trouble sleeping
troubled breathing with exertion
unexplained weight loss
unpleasant breath odor
unusual bleeding or bruising
unusual tiredness or weakness
unusual weight gain or loss
vomiting of blood
yellow eyes or skin
Blistering, peeling, or loosening of the skin
burning, numbness, tingling, or painful sensations
change in the ability to see colors, especially blue or yellow
difficulty with chewing or talking
double vision
drooping eyelids
eye pain
general feeling of tiredness or weakness
hives
hoarseness
irregular or slow heart rate
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
light-colored stools
muscle weakness
no blood pressure or pulse
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
red, irritated eyes
red skin lesions, often with a purple center
severe headache
severe tiredness
stomach pain, continuing
stopping of heart
unconsciousness
unsteadiness or awkwardness
unusual behavior, such as disorientation to time or place, failure to recognize people, hyperactivity, or restlessness
weakness in the arms, hands, legs, or feet
Acid or sour stomach
bad, unusual, or unpleasant (after) taste
belching
burning feeling in the chest or stomach
change in sense of smell
change in taste
changes in vision
continuing ringing or buzzing or other unexplained noise in the ears
difficulty having a bowel movement (stool)
excess air or gas in the stomach or intestines
fear or nervousness
feeling of constant movement of self or surroundings
full feeling
general feeling of discomfort or illness
hearing loss
heartburn
impaired vision
indigestion
itching of the vagina or genital area
lack or loss of strength
loss of memory
pain during sexual intercourse
passing of gas
problems with memory
redness, swelling, or soreness of the tongue
sensation of spinning
sleepiness or unusual drowsiness
sore mouth or tongue
stomach discomfort, upset, or pain
thick, white vaginal discharge with no odor or with a mild odor
white patches in the mouth or on the tongue